Citations

Showing 10 of 108094 citations.

Use of Cannabidiol in the Management of Insomnia: A Systematic Review
Ranum, Rylea, Whipple, Mary O. , Croghan, Ivana T. , Bauer, Brent, Vincent, Ann , Croghan, Ivana, Vincent, Ann , Whipple, Mary , Toussaint, Loren

Mayo Clinic

Cannabis & Cannabinoid Research | September 23, 2022 | Volume: 8 | Issue: 2 | Pages: 213-229

10.1089/can.2022.0122 | PMID 36149724 Get It

Background: Cannabidiol (CBD), one of the major cannabinoids derived from the cannabis plant, is available over the counter. CBD is often used by patients for the management of insomnia, yet research supporting CBDs effectiveness as a treatment for insomnia is inadequate. Objective: The objective of this review was to critically evaluate the literature regarding the therapeutic benefits of CBD in the management of insomnia. Methods: A comprehensive search of the following databases from inception to December 29, 2021, was conducted: Ovid MEDLINE ® and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search included randomized controlled trials, nonrandomized experimental studies, cross-sectional studies, cohort studies, case series, and case reports. Risk of bias was assessed with the Agency for Healthcare Research and Quality design-specific recommended criteria. Results: Thirty-four studies were eligible for inclusion. All studies reported improvement in the insomnia symptoms of at least a portion of their participants. Of the 34 studies, 19 studies used CBD predominant therapy and 21 studies used nearly equal ratios of CBD to Δ 9 -tetrahydrocannabinol (THC). Of the studies that performed hypothesis testing, 4 of 7 studies with a CBD predominant arm and 12 of 16 studies with a nearly equal ratio of CBD to THC arm reported significant improvement in insomnia outcomes. However, only 2 of the 34 studies focused on patients with insomnia, of which 1 study was a case report. Additionally, several studies used nonvalidated subjective measures, and most studies failed to include objective measures for symptom assessment. Conclusions: The results of our systematic review suggest that CBD alone or with equal quantities of THC may be beneficial in alleviating the symptoms of insomnia. Nevertheless, future research assessing CBDs effectiveness in population of patients specifically with insomnia utilizing validated subjective and objective measures is necessary before definitive inferences can be made.
Impact of atrial fibrillation on the risk of major adverse cardiac events following coronary revascularisation
Jung, Richard G. , Abdel‐Razek, Omar , Santo, Pietro Di , Gillmore, Taylor , Stotts, Cameron , Makwana, Dwipen, Soriano, Joelle , Moreland, Robert B. , Verreault‐Julien, Louis , Goh, Cheng Yee , Parlow, Simon , Sypkes, Caleb, Ramirez, Daniel F, Sadek, Mouhannad, Toeg, Hadi , Froeschl, Michael , Labinaz, Marino , Hibbert, Benjamin , Simard, Trevor , Hibbert, Benjamin , Abdel-Razek, Omar , Moreland, Robert, Ramirez, Daniel F., Sadek, Mouhannad M. , Chan, Vincent , Simard, Trevor

Mayo Clinic

Open Heart | September 23, 2022 | Volume: 9 | Issue: 2 | Pages: e002012

10.1136/openhrt-2022-002012 | PMID 36150746 Get It

Objective Atrial fibrillation (AF) remains a highly prevalent arrhythmia with significant burden on morbidity and mortality. The impact of AF in the revascularised population remains incompletely described. Given the high prevalence of AF in the revascularised population, we sought to evaluate the incidence and prognosis in patients with pre-existing and new-onset AF following revascularisation. Methods We used the University of Ottawa Heart Institute Revascularisation Registry to identify patients who underwent revascularisation between August 2015 and March 2020, who were prospectively followed for an average of one year. We conducted a retrospective cohort study analysing the association between AF and clinical outcomes. The primary outcome of interest was 1-year major adverse cardiac events (MACE) defined as a composite of death, myocardial infarction, unplanned revascularisation and cerebrovascular accidents. Moreover, secondary outcomes include the individual components of MACE and bleeding. Results A total of 6704 patients underwent revascularisation and completed 1-year clinical follow-up. Median time to follow-up was 12.8 (IQR 11.2–15.9) months. One-year MACE occurred in 166 (21.8%) and 683 (11.5%) patients in AF and non-AF groups, respectively (adjusted HR, 1.61; 95% CI 1.29 to 2.01; p<0.0001). AF was independently predictive of 1-year mortality, myocardial infarction, unplanned revascularisation, cerebrovascular accident and bleeding. Within 1 year, 299 (4.5%) episodes of new-onset AF was observed. New-onset AF following revascularisation was also associated with 1-year MACE, mortality, myocardial infarction, cerebrovascular accident and unplanned revascularisation. Conclusions Preprocedural and new-onset AF following revascularisation remains highly predictive 1-year MACE. AF should be considered in addition to traditional risk factors for adverse outcomes following revascularisation.
Correlation of the Modified Japanese Orthopedic Association With Functional and Quality-of-Life Outcomes After Surgery for Degenerative Cervical Myelopathy: A Quality Outcomes Database Study
Yee, Timothy J., Upadhyaya, Cheerag D., Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Turner, Jay D. , Knightly, Jack, Fu, Kai-Ming, Foley, Kevin T. , Tumialán, Luis M. , Shaffrey, Mark E., Bydon, Mohamad , Mummaneni, Praveen V. , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Asher, Anthony L. , Shaffrey, Christopher I. , Gottfried, Oren N., Than, Khoi D. , Wang, Michael Y. , Buchholz, Avery L., Haid, Regis W., Park, Paul

Mayo Clinic

Neurosurgery | September 23, 2022 | Volume: 91 | Issue: 6 | Pages: 952-960

10.1227/neu.0000000000002161 | PMID 36149088 Get It

BACKGROUND: The modified Japanese Orthopedic Association (mJOA) score is a widely used and validated metric for assessing severity of myelopathy. Its relationship to functional and quality-of-life outcomes after surgery has not been fully described. OBJECTIVE: To quantify the association of the mJOA with the Neck Disability Index (NDI) and EuroQol-5 Dimension (EQ-5D) after surgery for degenerative cervical myelopathy. METHODS: The cervical module of the prospectively enrolled Quality Outcomes Database was queried retrospectively for adult patients who underwent single-stage degenerative cervical myelopathy surgery. The mJOA score, NDI, and EQ-5D were assessed preoperatively and 3 and 12 months postoperatively. Improvement in mJOA was used as the independent variable in univariate and multivariable linear and logistic regression models. RESULTS: Across 14 centers, 1121 patients were identified, mean age 60.6 ± 11.8 years, and 52.5% male. Anterior-only operations were performed in 772 patients (68.9%). By univariate linear regression, improvements in mJOA were associated with improvements in NDI and EQ-5D at 3 and 12 months postoperatively (all P < .0001) and with improvements in the 10 NDI items individually. These findings were similar in multivariable regression incorporating potential confounders. The Pearson correlation coefficients for changes in mJOA with changes in NDI were −0.31 and −0.38 at 3 and 12 months postoperatively. The Pearson correlation coefficients for changes in mJOA with changes in EQ-5D were 0.29 and 0.34 at 3 and 12 months. CONCLUSION: Improvements in mJOA correlated weakly with improvements in NDI and EQ-5D, suggesting that changes in mJOA may not be a suitable proxy for functional and quality-of-life outcomes.
Prospective, randomized controlled multicenter study of posterior lumbar facet arthroplasty for the treatment of spondylolisthesis
Coric, Domagoj , Kim, Paul K., Welch, William C. , Robbins, Stephen E. , DeLuca, Steven, Whiting, Donald, Chahlavi, Ali, Pirris, Stephen M. , Groff, Michael W. , Chi, John H., Kent, Roland , Whitmore, Robert G. , Meyer, Scott A., Patel, Ashvin I., Orr, Robert D. , Krishnaney, Ajit A., Boltes, Peggy, Anekstein, Yoram , Steinmetz, Michael P. , Nassr, Ahmad , Chi, John H., Huang, Jason Haitao , Arnold, Paul M. , Orr, R. Douglas

Mayo Clinic

Journal of Neurosurgery: Spine | September 23, 2022 | Volume: 38 | Issue: 1 | Pages: 115-125

10.3171/2022.7.spine22536 | PMID 36152329 Get It

OBJECTIVE The purpose of this study was to evaluate the safety and efficacy of a posterior facet replacement device, the Total Posterior Spine (TOPS) System, for the treatment of one-level symptomatic lumbar stenosis with grade I degenerative spondylolisthesis. Posterior lumbar arthroplasty with facet replacement is a motion-preserving alternative to lumbar decompression and fusion. The authors report the preliminary results from the TOPS FDA investigational device exemption (IDE) trial. METHODS The study was a prospective, randomized controlled FDA IDE trial comparing the investigational TOPS device with transforaminal lumbar interbody fusion (TLIF) and pedicle screw fixation. The minimum follow-up duration was 24 months. Validated patient-reported outcome measures included the Oswestry Disability Index (ODI) and visual analog scale (VAS) for back and leg pain. The primary outcome was a composite measure of clinical success: 1) no reoperations, 2) no device breakage, 3) ODI reduction of ≥ 15 points, and 4) no new or worsening neurological deficit. Patients were considered a clinical success only if they met all four measures. Radiographic assessments were made by an independent core laboratory. RESULTS A total of 249 patients were evaluated (n = 170 in the TOPS group and n = 79 in the TLIF group). There were no statistically significant differences between implanted levels (L4–5: TOPS, 95% and TLIF, 95%) or blood loss. The overall composite measure for clinical success was statistically significantly higher in the TOPS group (85%) compared with the TLIF group (64%) (p = 0.0138). The percentage of patients reporting a minimum 15-point improvement in ODI showed a statistically significant difference (p = 0.037) favoring TOPS (93%) over TLIF (81%). There was no statistically significant difference between groups in the percentage of patients reporting a minimum 20-point improvement on VAS back pain (TOPS, 87%; TLIF, 64%) and leg pain (TOPS, 90%; TLIF, 88%) scores. The rate of surgical reintervention for facet replacement in the TOPS group (5.9%) was lower than the TLIF group (8.8%). The TOPS cohort demonstrated maintenance of flexion/extension range of motion from preoperatively (3.85°) to 24 months (3.86°). CONCLUSIONS This study demonstrates that posterior lumbar decompression and dynamic stabilization with the TOPS device is safe and efficacious in the treatment of lumbar stenosis with degenerative spondylolisthesis. Additionally, decompression and dynamic stabilization with the TOPS device maintains segmental motion.
Comparison of surgical interventions for the treatment of early-onset scoliosis: a systematic review and meta-analysis
Kim, Gloria, Sammak, Sally El , Michalopoulos, Giorgos D. , Freedman, Brett A. , Bydon, Mohamad , Mualem, William , Michalopoulos, Giorgos , Pinter, Zachariah W.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | September 23, 2022 | Volume: 31 | Issue: 4 | Pages: 342-357

10.3171/2022.8.peds22156 | PMID 36152334 Get It

OBJECTIVE Several growth-preserving surgical techniques are employed in the management of early-onset scoliosis (EOS). The authors’ objective was to compare the use of traditional growing rods (TGRs), magnetically controlled growing rods (MCGRs), Shilla growth guidance techniques, and vertically expanding prosthetic titanium ribs (VEPTRs) for the management of EOS. METHODS A systematic review of electronic databases, including Ovid MEDLINE and Cochrane, was performed. Outcomes of interest included correction of Cobb angle, T1–S1 distance, and complication rate, including alignment, hardware failure and infection, and planned and unplanned reoperation rates. The percent changes and 95% CIs were pooled across studies using random-effects meta-analysis. RESULTS A total of 67 studies were identified, which included 2021 patients. Of these, 1169 (57.8%) patients underwent operations with TGR, 178 (8.8%) Shilla growth guidance system, 448 (22.2%) MCGR, and 226 (11.1%) VEPTR system. The mean ± SD age of the cohort was 6.9 ± 1.2 years. The authors found that the Shilla technique provided the most significant improvement in coronal Cobb angle immediately after surgery (mean [95% CI] 64.3% [61.4%–67.2%]), whereas VEPTR (27.6% [22.7%–33.6%]) performed significantly worse. VEPTR also performed significantly worse than the other techniques at final follow-up. The techniques also provided comparable gains in T1–S1 height immediately postoperatively (mean [95% CI] 10.7% [8.4%–13.0%]); however, TGR performed better at final follow-up (21.4% [18.7%–24.1%]). Complications were not significantly different among the patients who underwent the Shilla, TGR, MCGR, and VEPTR techniques, except for the rate of infections. The TGR technique had the lowest rate of unplanned reoperations (mean [95% CI] 15% [10%–23%] vs 24% [19%–29%]) but the highest number of planned reoperations per patient (5.31 [4.83–5.82]). The overall certainty was also low, with a high risk of bias across studies. CONCLUSIONS This analysis suggested that the Shilla technique was associated with a greater early coronal Cobb angle correction, whereas use of VEPTR was associated with a lower correction rate at any time point. TGR offered the most significant height gain at final follow-up. The complication rates were comparable across all surgical techniques. The optimal surgical approach should be tailored to individual patients, taking into consideration the strengths and limitations of each option.
Catastrophic acute failure of pelvic fixation in adult spinal deformity requiring revision surgery: a multicenter review of incidence, failure mechanisms, and risk factors
Martin, Christopher T. , Holton, Kenneth J. , Elder, Benjamin D. , Fogelson, Jeremy L. , Mikula, Anthony L. , Kleck, Christopher J. , Calabrese, David W., Ou-Yang, David , Lovecchio, Francis , Hu, Serena S. , Wood, Kirkham B. , Harper, R. A. Kemp , Ananthakrishnan, Dheera , Schell, Adam, Lieberman, Isador H. , Kisinde, Stanley , DeWald, Christopher J., Colman, Matthew W. , Phillips, Frank M. , Gelb, Daniel E. , Bruckner, Jacob J. , Ross, Lindsey , Johnson, J. Patrick , Kim, Terrence T. , Anand, Neel , Plummer, Zach, Park, Paul , Oppenlander, Mark E., Polly, David W. , Polly, David , Burger, Evalina L. , Patel, Vikas V. , Kim, Han Jo , Harper, Robert, Michael, Keith W. , Nolte, Michael Thomas , Cheng, Joseph S. , Plummer, Zachary J., Sembrano, Jonathan N. , Jones, Kristen E.

Mayo Clinic

Journal of Neurosurgery: Spine | September 23, 2022 | Volume: 38 | Issue: 1 | Pages: 98-106

10.3171/2022.6.spine211559 | PMID 36057123 Get It

OBJECTIVE There are few prior reports of acute pelvic instrumentation failure in spinal deformity surgery. The objective of this study was to determine if a previously identified mechanism and rate of pelvic fixation failure were present across multiple institutions, and to determine risk factors for these types of failures. METHODS Thirteen academic medical centers performed a retrospective review of 18 months of consecutive adult spinal fusions extending 3 or more levels, which included new pelvic screws at the time of surgery. Acute pelvic fixation failure was defined as occurring within 6 months of the index surgery and requiring surgical revision. RESULTS Failure occurred in 37 (5%) of 779 cases and consisted of either slippage of the rods or displacement of the set screws from the screw tulip head (17 cases), screw shaft fracture (9 cases), screw loosening (9 cases), and/or resultant kyphotic fracture of the sacrum (6 cases). Revision strategies involved new pelvic fixation and/or multiple rod constructs. Six patients (16%) who underwent revision with fewer than 4 rods to the pelvis sustained a second acute failure, but no secondary failures occurred when at least 4 rods were used. In the univariate analysis, the magnitude of surgical correction was higher in the failure cohort (higher preoperative T1-pelvic angle [T1PA], presence of a 3-column osteotomy; p < 0.05). Uncorrected postoperative deformity increased failure risk (pelvic incidence–lumbar lordosis mismatch > 10°, higher postoperative T1PA; p < 0.05). Use of pelvic screws less than 8.5 mm in diameter also increased the likelihood of failure (p < 0.05). In the multivariate analysis, a larger preoperative global deformity as measured by T1PA was associated with failure, male patients were more likely to experience failure than female patients, and there was a strong association with implant manufacturer (p < 0.05). Anterior column support with an L5–S1 interbody fusion was protective against failure (p < 0.05). CONCLUSIONS Acute catastrophic failures involved large-magnitude surgical corrections and likely resulted from high mechanical strain on the pelvic instrumentation. Patients with large corrections may benefit from anterior structural support placed at the most caudal motion segment and multiple rods connecting to more than 2 pelvic fixation points. If failure occurs, salvage with a minimum of 4 rods and 4 pelvic fixation points can be successful.
Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid
Veer, Rozanne C. de , Harms, Maren H. , Thorburn, Douglas , Janssen, Harry L.A. , Nevens, Frederik , Lindor, Keith D. , Floreani, Annarosa , Ponsioen, Cyriel Y. , Mayo, Marlyn J. , Parés, Albert , Mason, Andrew L. , Bruns, Tony , Buuren, Henk R. van , Meer, Adriaan J. van der, Group, the Global PBC Study, van der Meer, Adriaan J , Invernizzi, Pietro , Lindor, K D , Mayo, Marlyn J , Mason, Andrew , Hirschfield, Gideon M , Bruns, Tony , Verhelst, Xavier , Corpechot, Christophe , Invernizzi, Pietro , Battezzati, Pier Maria , Kowdley, Kris V. , Trivedi, Palak Jitendrakumar , Hirschfield, Gideon M. , Dalekos, George Ν. , Gatselis, Nikolaos , Verhelst, Xavier , Lammers, Willem J. , Hansen, Bettina E. , Meer, Adriaan J. van der, Group, the Global PBC Study

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 23, 2022 | Volume: 56 | Issue: 9 | Pages: 1408-1418

10.1111/apt.17226 | PMID 36138566 Get It

SummaryBackgroundAfter 1 year of ursodeoxycholic acid (UDCA), patients with primary biliary cholangitis (PBC) may have a normal GLOBE score despite high alkaline phosphatase (ALP) levels.AimTo assess the association between ALP and liver transplantation (LT)‐free survival according to the GLOBE scoreMethodsAmong patients with a normal or elevated GLOBE score in the Global PBC cohort, the association between ALP after 1 year of UDCA and the risk of LT/death was assessed. The LT‐free survival was compared with that of a matched general population.ResultsAfter 1 year of UDCA, ALP was associated with the risk of LT/death (aHR 1.31, 95% CI 1.003–1.72, p = 0.048) among 2729 patients with a normal GLOBE score. The 10‐year LT‐free survival among these patients with an ALP >2.0 × ULN was 94.0% (95% CI 90.1–97.9) for those <50 years, and 82.6% (95% CI 76.5–88.7) for those ≥50 years, which was significantly lower (p = 0.040) and similar (p = 0.736) to that of the matched population, respectively. The 10‐year LT‐free survival in patients ≥50 years with normal GLOBE score and normal ALP (90.8%, 95% CI 87.7–93.9) was significantly higher (p = 0.022) than the matched population. Among 1045 patients with an elevated GLOBE score, ALP was associated with LT/death only in those <50 years (aHR 1.38, 95% CI 1.06–1.81, p = 0.016).ConclusionThe LT‐free survival of patients with PBC with a normal GLOBE score is optimal in case of normal ALP levels, also in relation to the general population. Despite their generally favourable prognosis, an elevated ALP level may still indicate a need for add‐on therapy.
An Expert Opinion/Approach: Clinical Presentations, Diagnostic Considerations, and Therapeutic Options for Gastrointestinal Manifestations of Common Variable Immune Deficiency
Squire, Jacqueline D. , Francis, Fadi, Binion, David G. , Cross, Raymond, Squire, Jacqueline, Hashash, Jana G. , Squire, Jacqueline , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | September 23, 2022 | Volume: 117 | Issue: 11 | Pages: 1743-1752

10.14309/ajg.0000000000002027 | PMID 36148549 Get It

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency. It is characterized by impaired B-cell differentiation. Although patients can be diagnosed with CVID anytime during their lifetime, most patients have symptoms for 5–9 years before their diagnosis. The diagnosis of CVID starts with a detailed history focusing on the infectious and noninfectious manifestations of the disease. In patients who are suspected to experience CVID, quantitative immunoglobulins (Ig) should be checked to confirm the diagnosis. IgG should be at least 2 times less than the age-specific SD along with either a low IgA or IgM and with evidence of impaired vaccine response. CVID is usually associated with infectious and/or noninfectious conditions, the latter of which can be inflammatory, autoimmune, lymphoproliferative, or malignant, among other manifestations. Ig therapy has positively affected the disease course of patients with infectious complications but has limited effect on the noninfectious manifestations because the noninfectious complications are related to immune dysregulation involving B cells and T cells rather than primarily due to antibody deficiency. When the gastrointestinal (GI) system is involved, patients with CVID may display signs and symptoms that mimic several GI conditions such as celiac disease, pernicious anemia, or inflammatory bowel diseases. The inflammatory bowel disease–like condition is usually treated with steroids, 5-aminosalicylates, thiopurines, or biologic agents to control the inflammation. In this review, the clinical presentations, diagnostic considerations, and therapeutic options for GI manifestations of CVID will be discussed to facilitate the individualized management of these often-complex patients.
A Review of Nuclear Imaging in Takotsubo Cardiomyopathy
Nayar, Jemimah , John, Kevin , Philip, Anil , George, Lina James , George, Anu Anna , Lal, Amos , Mishra, Ajay Kumar , Philip, Anil K. , George, Anu , Mishra, Ajay K , Lal, Amos , John, Kevin John

Mayo Clinic

Life | September 23, 2022 | Volume: 12 | Issue: 10 | Pages: 1476

10.3390/life12101476 | PMID 36294911 Get It

Takotsubo cardiomyopathy or Takotsubo Syndrome (TTS) is a reversible left ventricular dysfunction syndrome that is increasingly being recognized. Recent advances in nuclear imaging have allowed us to study TTS in greater detail. We searched the PubMed and Medline databases and identified 53 publications with 221 patients reporting nuclear imaging findings in TTS. The age of the patients ranged from 17 to 87 years and were predominantly women (88.2%). The TTS variant was apical (typical) in 170 (76.9%), mid-ventricular in 23 (10.4%), and basal (reverse TTS) in 2 (0.9%). Cardiac perfusion was assessed using 99mTc sestamibi (MIBI) SPECT, 99mTc tetrofosmin SPECT, 201Tl SPECT, 82Rb PET, 201Tl SPECT, and 13N ammonia PET. Additional studies used were 123I MIBG SPECT, 123I BMIPP SPECT, 18F FDG PET, 67Ga citrate, and 11C hydroxy-ephedrine. A perfusion defect was seen in 69 (31.2%), and an inverse perfusion–metabolism mismatch (normal or near-normal perfusion with absent myocardial metabolic activity) was seen in 183 (82.8%) patients. Nuclear imaging has a significant role in evaluating, diagnosing, and prognosticating patients with TTS. As nuclear imaging technology evolves, we will surely gain more insights into this fascinating disorder.
Dementia Care in the Last Year of Life: Experiences in a Community Practice and in Skilled Nursing Facilities
Bartley, Mairead M. , Manggaard, Jennifer M., Holland, Diane E. , Takahashi, Paul Y. , Bartley, Mairead M. , Fischer, Karen M.

Mayo Clinic

Journal of Palliative Care | September 23, 2022 | Volume: 38 | Issue: 2 | Pages: 135-142

10.1177/08258597221125607 | PMID 36148476 Get It

Objective People living with dementia often have high care needs at the end-of-life. We compared care delivery in the last year of life for people living with dementia in the community (home or assisted living facilities [ALFs]) versus those in skilled nursing facilities (SNFs). Methods A retrospective study was performed of older adults with a dementia diagnosis who died in the community or SNFs from 2013 through 2018. Primary outcomes were numbers of hospitalizations and emergency department visits in the last year of life. Secondary outcomes were completed advance care plans, hospice enrollment, time in hospice, practitioner visits, and intensive care unit admissions. Results Of 1203 older adults with dementia, 622 (51.7%) lived at home/ALFs; 581 (48.3%) lived in SNFs. At least 1 hospitalization was recorded for 70.7% living at home/ALFs versus 50.8% in SNFs ( P < .001), similar to percentages of emergency department visits (80.2% vs 58.0% of the home/ALF and SNF groups, P < .001). SNF residents had more practitioner visits than home/ALF residents: median (IQR), 9.0 (6.0-12.0) versus 5.0 (3.0-9.0; P < .001). No advance care plan was documented for 12.2% (n = 76) of the home/ALF group versus 4.6% (n = 27) of the SNF group ( P < .001). Nearly 57% of SNF residents were enrolled in hospice versus 68.3% at home/ALFs ( P < .001). The median time in hospice was 26.5 days in SNFs versus 30.0 days at home/ALFs ( P = .67). Conclusions Older adults with dementia frequently receive acute care in their last year of life. Hospice care was more common for home/ALF residents. Time in hospice was short.